XBIT Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

Stats
Объем за сегодня	59 095.00
Средний объем	73 349.00
Рыночная капитализация	239.65M
EPS	$-0.420 ( 2024-03-13 )
Дата следующего отчета о доходах	( $0 ) 2024-05-08
Last Dividend	$2.50 ( 2021-07-15 )
Next Dividend	$0 ( N/A )
P/E	-9.72
ATR14	$0.0510 (0.64%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Simard John	Buy	2 470 355	Convertible Loan Agreement
2023-06-23	Waldin Jan-paul	Buy	25 000	Director Stock Option
2023-06-23	Libby Peter	Buy	25 000	Director Stock Option
2023-06-23	Macadam Donald H.	Buy	25 000	Director Stock Option
2023-06-23	Mckenzie W Thorpe	Buy	25 000	Director Stock Option

INSIDER POWER
97.98
Last 100 transactions
Buy: 4 116 188 \| Sell: 11 979 897

Объем Корреляция

Длинно: -0.21 (neutral)

Кратко: -0.25 (neutral)

Signal:(51.714) Neutral

XBiotech Inc Корреляция

10 Самые положительные корреляции
VVOS	0.88
BPRN	0.871
BELFA	0.856
CGO	0.845
CNTY	0.845
PASG	0.84
APLD	0.838
DORM	0.831
BBCP	0.815
ATNX	0.812

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

XBiotech Inc Корреляция - Валюта/Сырье

0.42
( neutral )

-0.34
( neutral )

0.00
( neutral )

0.40
( neutral )

-0.26
( neutral )

-0.68
( moderate negative )

XBiotech Inc Финансовые показатели

Annual	2023
Выручка:	$0
Валовая прибыль:	$-1.74M (0.00 %)
EPS:	$-0.810

FY	2023
Выручка:	$0
Валовая прибыль:	$-1.74M (0.00 %)
EPS:	$-0.810

FY	2022
Выручка:	$4.01M
Валовая прибыль:	$3.36M (83.77 %)
EPS:	$-1.080

FY	2021
Выручка:	$18.39M
Валовая прибыль:	$12.57M (68.36 %)
EPS:	$-0.580

Financial Reports:

No articles found.

XBiotech Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

XBiotech Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$2.50	2021-07-15
Last Dividend	$2.50	2021-07-15
Next Dividend	$0	N/A
Payout Date	2021-07-23
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$2.50	--
Avg. Dividend % Per Year	1.55%	--
Score	0.63	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-28)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.63

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2021	$2.50	15.50%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-9.37	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.108	1.200	-3.60	-4.32	[0 - 0.3]
returnOnEquityTTM	-0.108	1.500	-2.31	-3.47	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	33.07	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	32.94	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	32.79	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-0.615	2.00	-0.205	-0.410	[0 - 30]
freeCashFlowPerShareTTM	-0.627	2.00	-0.314	-0.627	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.334	1.000	7.76	7.76	[0.2 - 0.8]
operatingProfitMarginTTM	-14.32	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.0115	0.800	-3.26	-2.61	[0.5 - 2]
Total Score				-0.390

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-9.75	1.000	-1.086	0	[1 - 100]
returnOnEquityTTM	-0.108	2.50	-1.487	-3.47	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.627	2.00	-0.209	-0.627	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.615	2.00	-0.205	-0.410	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.275	1.500	-5.17	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-7.15	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.34

XBiotech Inc

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.